As for Sézary syndrome, a rare leukemic type of CTCL, different expression patterns of NLRP3 and its effector cytokines were reported between different skin layers and LNs [127], a phenomenon that can be attributed to variable effects of NLRP3 inflammasome activation in the process of lymphomagenesis depending on the affected tissue. The gene discussed is NLRP3; the disease is primary cutaneous T-cell non-Hodgkin lymphoma.